Other
Paediatric-specific content in data standards for health
Turner, M.A.; Kalra, D.; Cornet, R.; Palmeri, A.; Sen, A.; Owen, J.; Pansieri, C.; Lee, J.; Hedley, V.; Nally, S.; Bonifazi, F.; Leary, R.;Straub, V.
Archives of Disease in Childhood Published Online First, 2025,DOI 10.1136/archdischild-2024-327931
Paediatric formulations—part of the repurposing concept?
Wang, S.; Giannuzzi, V.
Frontiers in Medicine, 11, 2024. DOI 10.3389/fmed.2024.1456247
Innovative research methodologies in the EU regulatory framework: an analysis of EMA qualification procedures from a paediatric perspective
Giannuzzi, V.; Bertolani, A.; Torretta, S.; Reggiardo, G.; Toich, E.; Bonifazi, D.; Ceci, A.
Front. Med. 2024, 11. DOI: 10.3389/fmed.2024.1369547
An overview of the efficacy and safety of deferiprone in paediatric patients with congenital haemoglobinopathies and chronic iron overload
Ceci A, Conte R, Didio A, Bonifazi D, Felisi M, Giannuzzi V, Bonifazi F.
Expert Opinion on Orphan Drugs. 2019; 7:4,181-197. doi: 10.1080/21678707.2019.1613977
9th European Conference on Rare Diseases & Orphan Products (ECRD Vienna 2018)
Giannuzzi V. Abandoned OMPs.
Orphanet Journal of Rare Diseases. 2018;13(S2)
Safe, Innovative and Accessible Medicines in Europe: A Renewed Strategy for Patients and the Pharmaceutical Sector
Altavilla A.
European Journal of Health Law. 2018;25(2):133-156. DOI: 10.1163/15718093-12520381
A Review on Impact of General Data Protection Regulation on Clinical Studies and Informed Consent
Giannuzzi V, Landi A, Bartoloni F, Ceci A.
J Clin Res Bioeth 2018; 9(3):327. doi: 10.4172/2155-9627.1000327
Formulating Medicines for children: challenges and issues - La Chimica e l'Industria (3): 2016
D'Andria P, Giannuzzi V, Bonifazi F, Ceci A, Denora N, Altomare C.
Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia
Botzenhardt S, Sing CW, Wong IC, Chan GC, Wong LY, Felisi M, Rascher W, Ceci A, Neubert A.
Curr Drug Saf. 2016;11(2):137-44
La Rete regionale degli acquisti della Regione Basilicata dall’Health technology assessment alla spesa: presentazione di un case study.
Lorusso S, Chiarolla E, Bonifazi F, Casino D, Sassano S.
Politiche Sanitarie. 2015;16(2):139-149
Availability of medicines for rare diseases in EU countries
Trama A, Pierannunzio D, Loizzo A, Taruscio D, Ceci A.
Pharmaceuticals Policy and Law, 2009;11(1,2):101-9
